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Abstract: Oxidative stress plays a pivotal role in the pathogenesis of inflammatory bowel diseases
(IBD). Serum free thiols (R-SH) reliably reflect systemic oxidative stress, since they are readily oxidized
by reactive species. Here, we aimed to establish concentrations of serum free thiols in IBD and
assessed their discriminating capacity regarding endoscopic disease activity. Albumin-adjusted serum
free thiol concentrations were measured in 78 IBD patients (31 Crohn’s disease (CD) and 47 ulcerative
colitis (UC) patients) and 50 healthy controls and analyzed for associations with disease parameters
and their discriminative value regarding endoscopic disease activity (n = 54) or fecal calprotectin
(n = 36) in patients for which those data were available. Mean serum free thiol concentrations were
significantly lower in both CD and UC as compared to healthy controls (19.4 ± 3.1 and 17.8 ± 3.4 vs.
21.1 ± 1.9 µmol/g albumin, P < 0.001). Free thiols highly accurately discriminated between mild and
moderate-to-severe disease activity, better than fecal calprotectin (FC) levels (AUC = 0.87, P < 0.001
vs. AUC = 0.76, P < 0.05, respectively) and this was maintained after cross-validation (AUC = 0.89,
P < 0.001). Serum free thiols are reduced in IBD as compared to healthy controls and strongly correlate
with the degree of endoscopic disease activity. Quantifying systemic redox status in IBD may be a
promising, minimally invasive strategy to monitor IBD disease activity.
Keywords: inflammatory bowel disease; oxidative stress; biomarkers; free thiols; disease activity;
fecal calprotectin
1. Introduction
Inflammatory bowel diseases (IBD), such as Crohn’s disease (CD) and ulcerative colitis (UC),
are chronic inflammatory intestinal disorders that are characterized by an inappropriate and ongoing
immune response, driven by dysregulated gut microbiota in genetically susceptible individuals [1].
Individuals affected by IBD typically show a disease course that consists of alternating exacerbations
and periods of remission [2]. It is challenging to accurately predict disease exacerbations due to their
highly variable symptomatology and the inadequate availability of surrogate disease biomarkers [3].
Most importantly, many IBD patients experience chronic subclinical disease activity, which may
be detrimental to patients’ health and increases the risk of disease complications and surgical
interventions [4].
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To determine the presence and extent of IBD disease activity, endoscopy is the gold-standard
diagnostic modality [5]. However, repeated endoscopic examination is accompanied by poor patient
acceptance, due to its invasive nature and the need for bowel preparation, sedation and a small risk of
complications. Moreover, it is a costly and time-consuming procedure. Clinical disease indices are
commonly applied to quantify patient-reported disease activity, though they fail to accurately represent
mucosal inflammation [6,7]. Hence, the diagnostic and predictive performances of surrogate markers
for endoscopic disease activity are increasingly being scrutinized. In this respect, fecal calprotectin (FC)
is currently considered to be the best discriminating biomarker for endoscopically proven inflammatory
disease activity [8,9]. Nevertheless, both its diagnostic accuracy for differentiating between different
degrees of disease activity and its clinical applicability are still subject to debate [10–12]. As a
consequence, novel surrogate markers for active mucosal inflammation are actively sought for to
monitor disease activity and detect IBD exacerbations early.
Oxidative stress, characterized by an excessive production of reactive oxygen species (ROS)
and decreased antioxidant availability, is believed to play a pivotal role in IBD etiology and
progression [13,14]. Systemic oxidative stress is associated with decreased levels of reduced free
thiols, since thiols are rapidly oxidized by circulating reactive species [15]. Serum free thiols (R-SH,
sulfhydryl groups) are a robust and powerful read-out of the systemic in vivo reduction-oxidation
(redox) status [16]. Blood proteins, mainly albumin, harbor the largest amount of redox-active thiol
groups (approximately 75% of the total thiol pool) [17]. The remainder is accounted for by the group
of low-molecular-weight (LMW) thiols, such as cysteine, glutathione and homocysteine. These LMW
thiols are present at very low concentrations in the extracellular environment, and predominantly
circulate complexed with albumin [16]. Typically, high extracellular concentrations of reduced free
thiols are representative of a healthy redox status.
Previous studies have examined systemic free thiol levels in a variety of conditions, including
cardiovascular, renal, metabolic and rheumatological diseases [18–21]. These studies show positive
associations between free thiol levels and favorable disease outcomes. On the other hand, decreased
free thiols have been linked to cardiovascular risk factors, such as ageing, obesity and alcohol
consumption [22,23]. Earlier, we already demonstrated that CD patients had markedly reduced levels
of systemic free thiols, even in clinical remission [24]. However, since that CD cohort lacked sufficient
information about endoscopic disease activity, we could not fully evaluate the possible role of free
thiols as biomarker for mucosal disease activity. Over the past decades, many studies have been
performed to assess oxidative stress biomarkers in IBD, though few of them addressed the potential
ability of such biomarkers to categorize different grades of endoscopic disease activity in IBD [25,26].
In the present study, we aimed to determine and compare systemic free thiol concentrations
between CD, UC and healthy individuals and to establish associations between serum free thiol
concentrations and IBD-specific disease parameters, especially those related to inflammatory disease
activity. Finally, we aimed to assess the discriminative accuracy of serum free thiol levels with regard
to different degrees of endoscopic disease activity in IBD and compare this to fecal calprotectin levels.
2. Materials and Methods
2.1. Study Population
From October 2014 until December 2018, 78 IBD patients aged 18–65 years were invited to
participate in the study at the IBD outpatient clinic of the University Medical Center Groningen
(UMCG), Groningen, The Netherlands. All patients had an established IBD diagnosis existing for at
least 1 year according to clinical, endoscopic and histopathological criteria [27]. At time of inclusion,
all patients presented with at least some degree of active disease necessitating new biological therapy,
and 56.4% of patients were treated with conventional IBD treatment (e.g., mesalamine, thiopurines,
or any combination of these drugs).
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2.2. Data Collection
Demographic characteristics of the participants were collected, including age, sex, body mass
index (BMI, body weight divided by squared height) and smoking status. Clinical characteristics were
registered for the complete IBD cohort, including the Montreal disease classification, IBD maintenance
medication (mesalamine, thiopurines, or any combination of these drugs), prior use of TNF-antagonists,
IBD-related surgical history (ileocecal resection for CD and subtotal colectomy for UC) and clinical
disease indices (Harvey Bradshaw index (HBI) for CD and Simple Clinical Colitis Activity Index
(SCCAI) for UC) [28,29]. Disease location according to the Montreal classification was registered from
the most recently performed endoscopic assessment, at least within 12 months of serum analysis.
CD patients having upper gastrointestinal disease or active perianal disease were not included in the
study. Standard laboratory measurements were performed in all participants, including hemoglobin
(Hb), C-reactive protein (CRP), white blood cell count (WBC), platelet count, albumin and creatinine
(Roche Modular, Roche, Mannheim, Germany). The estimated glomerular filtration rate (eGFR)
was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation [30]. In the IBD cohort, fecal calprotectin (FC) levels were detected in a subgroup of
patients (n = 36) using enzyme-linked immunosorbent assays (ELISA) (Bühlmann Laboratories AG,
Switzerland). In another subset of IBD patients (69.2%, n = 54), endoscopic disease activity was assessed
within 3 months prior to serum sample analysis (77.7% within 1 month). Endoscopic disease activity
was graded according to the validated Simplified Endoscopic Score for Crohn’s disease (SES-CD) for CD
or the Mayo endoscopic subscore for UC [31,32], based on available endoscopic images and endoscopy
reports written by certified gastroenterologists from our university hospital. All included patients
who underwent endoscopic investigation had at least mild disease activity. Consequently, SES-CD
scores fell into one of the following three activity categories: (1) mild (SES-CD 4–10), (2) moderate
(SES-CD 11–19) or (3) severe (SES-CD ≥ 20) [33]. Similarly, Mayo endoscopic subscores are covered in
the three categories (1) mild (Mayo 1), (2) moderate (Mayo 2) and (3) severe (Mayo 3). Additionally,
for the purpose of total (IBD) cohort analyses, CD and UC patients falling into the same endoscopic
categories were merged to create a composite IBD endoscopic disease activity assessment.
2.3. Measurement of Serum Free Thiols
Serum samples were stored at −80◦C until free thiol analysis. Sample storage at this temperature
does not significantly alter free thiol stability. Samples from IBD patients and non-IBD controls were
obtained according to the same protocols. Serum free thiol concentrations were measured as previously
described, with few modifications [34,35]. As a first step, serum samples were diluted 4-fold using 0.1 M
Tris buffer (pH 8.2). After measuring background absorption at 412 nm using the Varioskan microplate
reader (Thermo Scientific, Breda, The Netherlands), together with a reference measurement at 630 nm,
20 µL 1.9 mM 5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB, Ellman’s Reagent, CAS-number 69-78-3,
Sigma Aldrich Corporation, St. Louis, MO, USA) in 0.1 M phosphate buffer (pH 7.0) was added to the
samples. Absorbance was measured again after an incubation time of 20 min at room temperature.
Final concentrations of free thiol groups were determined by parallel measurement of an l-cysteine
(CAS-number 52-90-4, Fluka Biochemika, Buchs, Switzerland) calibration curve (concentration range
from 15.6 µM to 1000 µM) in 0.1 M Tris/10 mM EDTA (pH 8.2). Both intra- and interday coefficients of
variation (CV) of the free thiol measurements were <10%. Finally, serum free thiol concentrations were
adjusted for serum albumin levels by calculating the free thiol groups/albumin ratio. This adjustment
was performed since albumin is the predominant blood protein and therefore largely determines the
total quantity of potentially detectable free thiol groups [17].
2.4. Statistical Analysis
Demographic and clinical characteristics of the study population were presented as means ±
standard deviations (SD), proportions n with corresponding percentages (%) or medians (interquartile
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range (IQR)) in case of skewed distributions. Normality testing was performed using histograms,
normal probability plots (Q–Q plots) and the D’Agostino and Pearson’s omnibus K2 normality test [36].
Comparisons between groups for continuous variables were performed using independent sample
t-tests, Mann–Whitney U-tests, one-way analysis of variance (ANOVA) or the Kruskal-Wallis test,
while for nominal variables chi-square tests or Fisher’s exact tests were performed, as appropriate.
IBD patients were subdivided into two groups of below- and above-average serum free thiol
concentrations and compared for demographic, clinical and biochemical parameters. Univariable and
multivariable linear regression analyses were performed to identify variables that were independently
associated with serum free thiol concentrations. Multivariable linear regression was executed using
backward selection (Pout > 0.05), with inclusion of all significantly associated variables from univariable
analysis. Non-normally distributed continuous variables were logarithmically transformed before
entry into linear regression analysis. Independent associations were visualized in scatter plots
showing Pearson’s product-moment correlation coefficient. To evaluate discriminative capacity
of albumin-adjusted serum free thiols regarding endoscopic disease activity, receiver operating
characteristics (ROC) analyses were performed with the calculated area under the curve (AUC)
as overall measure of fit. ROC curves and AUC values were calculated using the nonparametric,
tie-corrected trapezoidal approximation method. Univariable logistic regression analysis was used to
identify potentially confounding factors, which were included as covariate in a multivariable logistic
regression model to adjust for these factors. The final predictive model of albumin-adjusted serum
free thiols with covariate adjustment (derived from multivariable logistic regression analysis) was
internally validated using k-fold cross-validation (k = 10). To do this, the dataset was randomly
partitioned into k approximately equally sized parts. Each part was then left out (10% of cases) while
the model was fitted to the remaining k – 1 parts (90% of cases, ‘training set’) and predictions were
obtained for the left-out kth part (‘test set’). This procedure was repeated 10 times, so each part
acted as test set. Finally, AUCs from each fold were averaged and bootstrapped to achieve statistical
inference, resulting in a cross-validated AUC with a corresponding 95% confidence interval (CI).
Where appropriate, corrections for multiple comparisons were applied using the Bonferroni correction.
Data analysis was performed using SPSS Statistics 25.0 software package (SPSS Inc., Chicago, IL, USA)
and Stata 15.1 (Stata Corp LLC, College Station, TX, USA) using the commands ‘roctab’, ‘rocreg’ and the
CVAUROC module (github link: https://github.com/migariane/cvAUROC) [37]. Data were visualized
using GraphPad Prism 5.0 (GraphPad software, San Diego, CA, USA). Two-tailed P-values ≤ 0.05 were
considered statistically significant.
2.5. Ethical Considerations
Serum samples of IBD patients were obtained after they provided written informed consent.
This study was approved by the Institutional Review Board (IRB) of the University Medical
Center Groningen (UMC Groningen) (in Dutch: ‘Medisch Ethische Toetsingscommissie’, METc)
(IRB no. 2018/703). In addition, serum samples of 50 healthy, non-IBD controls were retrieved
from a UMCG biobank containing pre-donation samples of living kidney donors (PSI-UMCG
(IRB no. 2008/279)). The study was performed in accordance with the principles of the Declaration of
Helsinki (2013).
3. Results
3.1. Cohort Demographic and Clinical Characteristics
The study cohort consisted of 78 IBD patients (47 UC patients and 31 CD patients) and 50 healthy
controls (HC). Study groups were matched for gender (IBD: 46.2% females vs. HC: 46.0% females,
P = 0.99). Age was significantly different between patients with IBD and HC (mean ± SD: 43.3 ± 8.5 vs.
50.7 ± 8.5 years, respectively, P < 0.01) and was adjusted for in all analyses when HC were involved.
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Most IBD patients had clinically active disease (76.7% with HBI or SCCAI score > 5). All shared
characteristics between patients with IBD and HC are presented in Table 1.
Table 1. Baseline characteristics of IBD patients and healthy controls (HC).
Variables HC IBD P-Value
n = 50 n = 78
Serum free thiols per gram of albumin (µmol/g) 21.1 ± 1.9 18.5 ± 3.4 <0.001
Age (years) 50.7 ± 8.5 43.3 ± 8.5 <0.01
Female, n (%) 23 (46.0) 36 (46.2) 0.99
BMI (kg/m2) 26.9 ± 3.1 24.8 ± 4.9 <0.01
Current smoking, n (%) 13 (26.0) 13 (18.8) 0.35
Laboratory Measurements
Hemoglobin (g/dL) 14.8 ± 1.3 12.3 ± 1.8 <0.001
CRP (mg/L) * 1.0 (0.6–1.5) 4.1 (1.2–10.3) <0.001
WBC (×109/L) * 6.7 (5.4–7.8) 7.6 (6.0–10.3) <0.01
Platelets (×109/L) * 244 (207–296) 308 (259–376) <0.001
Albumin (g/L) 45.6 ± 2.3 40.1 ± 3.9 <0.001
eGFR (mL/min * 1.73m2) 87.7 ± 14.5 102.4 ± 26.4 <0.01
Creatinine (µmol/L) 81.5 ± 15.9 73.1 ± 21.1 <0.05
Data are presented as mean ± SD or proportions (n, %). * Skewed data are presented as median (interquartile range).
P-values were two-tailed and calculated using independent sample t-tests or Mann–Whitney U-tests, as appropriate.
Abbreviations: IBD, inflammatory bowel disease; CD, Crohn’s disease; HC, healthy controls; BMI, body mass index;
CRP, C-reactive protein; WBC, white blood cell count; eGFR, estimated glomerular filtration rate. Bold P-values
indicate statistical significance.
3.2. Serum Levels of Free Thiols are Markedly Decreased in IBD
Serum levels of albumin-adjusted free thiols were significantly lower in both CD (19.4 ± 3.1 µmol/g,
P < 0.05) and UC (17.8 ± 3.4 µmol/g, P < 0.001) patients, as compared to HC (21.1 ± 1.9 µmol/g)
(Figure 1). In addition, serum albumin-adjusted free thiol levels were significantly reduced in UC as
compared to CD (P < 0.05). However, this was not significant after correction for multiple testing
(P = 0.05). In all groups, albumin-adjusted serum free thiol levels were normally distributed (CD,
P = 0.37; UC, P = 0.43; HC, P = 0.14) (Figure S1).
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Figure 1. Albumin-adjusted serum free thiols (R-SH) (µmol/g) are highly significantly reduced in both
Crohn’s disease (CD) and ulcerative colitis (UC) patients as compared to healthy controls (* P < 0.05
and *** P < 0.001, respectively).
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3.3. Associations between Serum Albumin-Adjusted Free Thiols and IBD Parameters
Disease parameters of IBD patients are summarized in Table 2 with a comparison between patients
with below-average albumin-adjusted serum free thiols (<18.5 µmol/g) (n = 40) and above-average
albumin-adjusted serum free thiols (>18.5 µmol/g) (n = 38). IBD patients with below-average
albumin-adjusted serum free thiols had significantly higher WBC (median (IQR) 8.7 (6.5–12.5) vs.
6.5 (5.3–9.2) × 109/L, P < 0.01), platelets (339 (283–402) vs. 290 (236–331) × 109/L, P < 0.05) and fecal
calprotectin levels (1465 (929–2420) vs. 600 (255–1220) µg/g, P < 0.01), whereas disease duration was
shorter (6.0 (2.0–11.0) vs. 9.0 (3.8–13.0) years, P < 0.05) and eGFR was significantly lower (mean ± SD
95.8 ± 22.9 vs. 109.0 ± 28.4 mL/min/1.73 m2, P < 0.05). No significant differences in albumin-adjusted
serum free thiol concentrations were observed for different disease localization according to the
Montreal classification (CD, P = 0.15; UC, P = 0.46) (Figure S2).
Table 2. Baseline demographic, clinical and IBD-specific characteristics compared between above- and






n = 78 n = 40 n = 38
Serum free thiols per gram of albumin
(µmol/g) 18.5 ± 3.4 15.9 ± 2.1 21.1 ± 2.2 <0.001
Age (years) 43.3 ± 8.5 44.4 ± 16.7 42.1 ± 13.8 0.51
Female, n (%) 36 (46.2) 17 (42.5) 19 (50.0) 0.51
BMI (kg/m2) 24.8 ± 4.9 24.4 ± 4.9 25.2 ± 4.9 0.49
Current smoking, n (%) 13 (18.8) 7 (21.1) 6 (16.7) 0.63
Prior surgery, n (%) 21 (26.9) 7 (17.5) 14 (36.8) 0.06
Disease duration (years)* 7.0 (3.0–12.3) 6.0 (2.0–11.0) 9.0 (3.8–13.0) <0.05
Prior anti-TNF, n (%) 67 (85.6) 32 (80.0) 35 (92.1) 0.28
HBI/SCCAI* 6 (5–10) 6 (4.8–10.0) 6.5 (4.8–10.3) 0.93
Disease Location (CD), n (%) 0.05
n = 31 n = 12 n = 19
L1 (ileal) 6 (19.4) - 6 (31.6)
L2 (colonic) 4 (12.9) 3 (25.0) 1 (5.3)
L3 (ileocolonic) 21 (67.7) 9 (75.0) 12 (63.2)
Disease Extent (UC), n (%) 0.54
n = 47 n = 28 n = 19
E1 (proctitis) - - -
E2 (left-sided colitis) 15 (31.9) 10 (35.7) 5 (26.3)
E3 (pancolitis) 32 (68.1) 18 (64.3) 14 (73.7)
Age at Diagnosis (Montreal A) 0.32
A1 (< 16 years) 10 (12.8) 5 (12.5) 5 (13.2)
A2 (17 – 40 years) 50 (64.1) 23 (57.5) 27 (71.1)
A3 (> 40 years) 18 (23.1) 12 (30.0) 6 (15.8)
Medication, n (%) 0.28
None 34 (43.6) 20 (50.0) 14 (36.8)
Thiopurines 19 (24.4) 7 (17.5) 12 (31.6)







Mesalamine 18 (23.1) 8 (20.0) 10 (26.3)
Combination 7 (9.0) 5 (12.5) 2 (5.3)
Laboratory Measurements
Hemoglobin (g/dL) 12.3 ± 1.8 12.1 ± 1.6 12.4 ± 1.9 0.32
CRP (mg/L)* 4.1 (1.2–10.3) 4.1 (1.0–12.5) 3.9 (1.2–9.2) 0.77
ESR (mm/h)* 17.0 (6.0–41.3) 22.5 (7.0–40.1) 13.5 (4.0–44.3) 0.42
WBC (×109/L)* 7.6 (6.0–10.3) 8.7 (6.5–12.5) 6.5 (5.3–9.2) <0.01
Platelets (×109/L)* 308 (259–376) 339 (283–402) 290 (236–331) <0.05
Albumin (g/L) 40.1 ± 3.9 40.6 ± 3.4 39.6 ± 4.3 0.270
eGFR (mL/min/1.73 m2) 102.4 ± 26.4 95.8 ± 22.9 109.0 ± 28.4 <0.05
Creatinine (µmol/L) 73.1 ± 21.1 77.1 ± 24.1 69.0 ± 16.7 0.091
Fecal calprotectin (µg/g)*,† 1220(610–1885) 1465 (929–2420) 600 (255–1220) <0.01
Data are presented as mean ± SD or proportions (n, %). *Skewed data are presented as median (interquartile
range). †Fecal calprotectin levels were only measured in a subset of patients (n = 36). P-values were two-tailed
and calculated using independent sample t-tests or Mann–Whitney U-tests, as appropriate. P-values < 0.05 were
considered statistically significant (indicated in bold). Abbreviations: CD, Crohn’s disease; UC, ulcerative colitis;
BMI, body mass index; HBI, Harvey Bradshaw index; SCCAI, simple clinical colitis activity index; TNF, tumor
necrosis factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; eGFR,
estimated glomerular filtration rate.
Using univariable and multivariable linear regression analyses, age (r = −0.49, P < 0.01), disease
duration (r = 0.39, P < 0.05), platelets (r = −0.29, P < 0.01) and fecal calprotectin levels (r = −0.32,
P < 0.05, n = 36) were independently associated with albumin-adjusted serum free thiols in the IBD
cohort (Table 3 and Figure S3). In the CD cohort, platelets (r = −0.51, P < 0.05) and disease duration
(r = 0.39, P < 0.05) were independently associated, whereas in the UC cohort, the white blood cell count
(WBC) (r = −0.41, P < 0.05) and Simple Clinical Colitis Activity Index (SCCAI) (r = −0.34, P < 0.05)
were independently associated with albumin-adjusted serum free thiols (Tables S1 and S2).
Table 3. Univariable and multivariable linear regression analyses of albumin-adjusted serum free thiols
in IBD with clinical and biochemical parameters.
Serum Free Thiols/Gram of Albumin Univariable Analysis Multivariable Analysis
Variables B Coefficient # P-Value B Coefficient # P-Value
Age −0.237 0.04 † −0.500 <0.01 †
Female sex 0.093 0.42
Current smoker −0.054 0.66
BMI −0.042 0.73
Disease duration * 0.288 <0.05 † 0.364 <0.05 †
Prior anti-TNF 0.180 0.11
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Table 3. Cont.
Serum Free Thiols/Gram of Albumin Univariable Analysis Multivariable Analysis
Laboratory Measurements
Hemoglobin 0.102 0.37
CRP * −0.007 0.95
ESR * −0.128 0.27
WBC * −0.338 <0.01 †
Platelets * −0.223 0.05 † −0.278 <0.05 †
Albumin −0.127 0.27
eGFR 0.370 <0.01 †
Creatinine −0.235 0.04 †
Fecal calprotectin * −0.422 0.01 † −0.345 <0.05 †
* Skewed data have been logarithmically transformed before entry into analyses. # Standardized beta (β) coefficient.
† P-values < 0.05 were considered statistically significant (indicated in bold). Abbreviations: BMI, body mass
index; HBI, Harvey Bradshaw index; SCCAI, simple clinical colitis activity index; TNF, tumor necrosis factor; CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; WBC, white blood cell count; eGFR, estimated glomerular
filtration rate.
3.4. Serum Free Thiols Strongly Correlate with Endoscopic Disease Activity
In a subset of patients (n = 54, 69.2%), an endoscopy procedure was performed close to the day
that serum samples were collected for routine biochemistry and free thiol analysis. Albumin-adjusted
serum free thiols were significantly associated with endoscopic disease activity (Figure 2). IBD patients
with severe endoscopic disease activity had significantly lower levels of albumin-adjusted serum
free thiols compared to patients with mild disease activity (16.2 ± 3.1 µmol/g vs. 20.4 ± 3.4 µmol/g,
P < 0.01) (Figure 2A). Stratified by IBD subtype, both CD and UC patients with severe disease activity
exhibited significantly reduced levels of albumin-adjusted serum free thiols compared to patients with
mild disease activity (CD, 16.6 ± 0.8 µmol/g vs. 20.0 ± 2.3 µmol/g, P < 0.05; UC, 16.2 ± 3.4 µmol/g vs.
20.8 ± 4.7 µmol/g, P < 0.05) (Figure 2B,C).
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Figure 2. Albumin-adjusted serum free thiols are significantly decreased in (A) IBD patients, (B) CD
patients and (C) UC patients with severe endoscopic disease activity as compared to mild disease
activity (** P < 0.01; * P < 0.05).
3.5. Discriminative Accuracy of Serum Free Thiols regarding Endoscopic Disease Activity
As a next step, albumin-adjusted serum free thiols were evaluated in terms of their discriminative
accuracy to differentiate mild disease activity (SES-CD or Mayo cat gory 1) from moderate-to-sever
endoscopic dis ase activity (SES-CD or Mayo cat gories 2 and 3) (Figure 3). In the IBD cohort,
serum lev ls of albumi -adjusted free thiols significantly discriminated patients with mild disease
activity from patients with moderate-to-severe diseas activity (area under the curve (AUC) = 0.76,
95% confidence interval (CI) 0.64–0.89, P < 0.01, Figure 3A and Table S3). For comp rison, the AUC
for fecal calprotectin levels was 0.66 (95% CI 0.42–0.89, P = 0.23, n = 28, Figure 3B and Table S3).
Fecal calpr tec in levels clos st to the date of endo copy were incorporated into this analysis (n = 28,
medi (IQR) time interval: 30 (21–50) day , all within 3 months). After adjustment for tentially
confounding factors derived from univariable logistic regression analysis (Table S4), serum free thiols
remained superior to fecal calprotectin levels in discriminating between mild and moderate-to-severe
endoscopic disease activity (AUC 0.87, 95% CI 0.78–0.97, P < 0.001 vs. AUC 0.76, 95% CI 0.56–0.96,
P < 0.05, respectively) (Figure 3C,D). This final adjusted model containing serum free thiols maintained
its discriminative ability after k-fold cross-validation (k = 10), which resulted in an AUC of 0.89 (95%
CI 0.68–0.93, P < 0.001) (Figure S4 and Table S5).
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and moderate-to-severe (2,3) endoscopic disease activity as compared to fecal calprotectin levels (B),
even after adjustment for potentially confounding factors (C–D).
4. Discussion
We demonstrate that albumin-adjusted serum free thiols are significantly correlated to endoscopic
disease activity i IBD. Also, serum albumin-a justed free thiols are superior in terms of their ability
to iscrim nate between mild and moderate-to-severe disea e activity as compared to FC levels
(AUC = 0.87, P < 0.001 vs. AUC = 0.76, P < 0.05). In the final adjusted model, albumin-adjusted
serum fr e thiols very accurately discriminated between mild and moderate-to-severe isease activity,
confir ed by an AUC of 0.89 aft r cross-validation. F th rmore, albumin-adjusted s rum free thiol
concentration w significantly lower in IBD as compared to healthy individuals, with lower v lues
in pati nts with UC as compar to those with CD. Fi ally, in the IBD cohort, serum concentrations of
albumin-adjusted free thiols were significantly inversely associated with age, platelet counts and fecal
calprotectin (FC) levels, and p sitively associated with durati n of disease.
Our s udy is th first to explore e potential use of serum fr e thio s as a surrogate measure
of systemic oxidative stress to ssess disease activity in IBD. Earlier studies have assessed a variety
of other oxidative stress biomarkers in IBD and related them to disease activity. For instance,
it has repeate ly been dem n trate th t IBD patients show a lower total blood antioxidant status,
as r flecte by decreased total antioxidant capacity (TAC) and low l vels of anti x dants such as
β-caro ne, glutathione pe oxi ase (GPx), sup roxide dismutase (SOD) and catalase (CAT) [38–41].
Howev r, in these studies, correla ns with disease activity remain inconsistent. Most notably, nearly
all of these studies established their correlations with isea e ac ivity based on clinical symptom scores.
Similarly, such conflicting results even exist within our own study, since we observ d an independent
significant association between serum free thiols and the SCCAI score for UC, whereas no significant
correlation was found with the HBI score for CD. However, there are hardly any studies evaluating
oxidative stress biomarkers that focused on relationships with validated endoscopy scores, used to
define the degree of endoscopic disease activity [42,43]. In the case of UC, there are few studies in which
a significant correlation was detected between the endoscopic activity index (EAI) and total oxidant
status (TOS) levels, as measured by a spectrophotometric assay [42]. Another study investigated
associations between the Mayo endoscopic subscore and serum levels of the antioxidant enzymes GPx,
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SOD-1 and CAT, though these associations were all non-significant [43]. In contrast, we observed a
clear correlation between serum free thiols and endoscopic disease activity scores, both in the total
IBD cohort and for CD and UC patients separately. Perhaps this observation may be explained by
the fact that the measurement of serum free thiol concentrations provides a more accurate indication
of systemic redox status as compared to individual oxidant or antioxidant substances and derived
products [16].
Results from the present study further emphasize the potential significance of serum free thiols
as an integrative marker of human systemic redox status. Serum free thiol groups (R-SH, serum
sulfhydryl status) are representative of an intricate and dynamic extracellular redox regulation system
with potent antioxidant activity, since they act as a major scavenger of circulating reactive species [16].
Extracellular thiols are largely embedded in proteins, whereas a smaller fraction of the total thiol
pool is represented by low molecular weight (LMW) thiols, such as cysteine, glutathione (GSH)
and homocysteine, which exist in both reduced and oxidized forms [44]. However, LMW thiols
predominantly control intracellular redox status and are of lesser importance to redox regulation
within the extracellular compartment [17]. Blood proteins contain the largest amount of thiols. In this
respect, serum albumin is quantitatively the most important (based on its single free cysteine residue,
Cys34), not only because of its abundance, but also given its transporting capacity of LMW thiols [17].
In the present study, we only measured serum free thiol concentrations and adjusted these to serum
albumin levels, which can be regarded as an indirect approach to more precisely reflect the total serum
thiol pool [45].
In this study, we found independent associations between serum free thiols and age, duration of
disease, platelets and fecal calprotectin levels. The inverse correlation between age and serum free
thiols corroborates the findings of previous studies [18,23]. Serum free thiol concentrations decrease
with age, which is putatively caused by a combination of compromised antioxidant availability,
an age-related increase in ROS production and a decreased ratio of reduced vs. oxidized forms of
serum albumin [23]. Counterintuitively, we observed a positive association between serum free thiols
and duration of disease. Contradictory to this finding, there is considerable evidence suggesting
that longer-term exposure to oxidative stress, with continuous ROS generation and deteriorating
antioxidant defense, further aggravates ROS-mediated tissue damage and concomitant inflammatory
activity [26,46,47]. In fact, oxidative stress is believed to be a key mechanism in disease progression of
IBD. Nevertheless, it should be taken into account that most IBD patients follow a highly unpredictable,
chronic intermittent disease course, from which a dynamic association may arise between disease
duration and inflammatory activity or oxidative stress [48]. Indeed, in our study, patients with
relatively longer disease duration had more often less severe disease activity compared to patients
with shorter IBD history, though this difference was not statistically significant. Lastly, we detected an
independent significant association between platelet counts and serum free thiol concentrations. It is
well recognized that high platelet counts (thrombocytosis) coincide with inflammatory activity and
oxidative stress in IBD [49]. For instance, platelets have been shown to be of predictive value regarding
endoscopic disease activity in IBD [50].
Intriguingly, our data demonstrate that FC levels were significantly negatively correlated to
albumin-adjusted serum free thiols. The observed significant correlation is consistent with a recent
study in which significant correlations were observed between FC levels and the serum antioxidant
enzymes GPx and CAT [51]. These authors hypothesized that these correlations, based on another
study on polymorphonuclear neutrophils, could originate from the fact that FC has pro-oxidant
properties by boosting the formation of ROS [52]. FC is a protein dimer complex (S100A8/S100A9)
representing approximately 60% of cytosolic proteins of neutrophilic granulocytes and is released upon
the process of intestinal inflammation [53]. Therefore, increased neutrophilic inflammatory disease
activity, as represented by elevated FC levels, accompanied by increased oxidative stress, may likely
be mirrored by a decrease in the total pool of serum free thiols. Subsequently, the increased level of
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oxidative stress may induce a compensatory production of antioxidant enzymes to counteract ROS
activity and restore thiol homeostasis [51].
In this study, we showed that serum free thiols were able to accurately discriminate between
mild and moderate-to-severe endoscopic disease activity in our cohort of IBD patients. Although
this promising result should be further validated in larger, prospective validation cohorts, it may
be particularly relevant as discriminating between different degrees of active disease may help in
guiding therapeutic decisions and adjusting medical therapy [54]. In addition, endoscopic assessment
of disease activity (commonly referred to as ‘mucosal healing’) is emerging as an important therapeutic
endpoint in clinical trials [55]. As future assessment of endoscopic disease activity may be found in the
measurement of serum biomarkers, this study is aimed to serve as a stepping stone for future studies
that could evaluate the potential of serum free thiols as biomarkers for (endoscopic) disease activity
in IBD.
Strengths of our study include the extensive characterization of the patient cohort and the
control group, which allowed us to directly compare serum free thiol concentrations between IBD
and healthy individuals. Additionally, our study was fueled by sufficient study power to be able to
reliably establish differences between groups and to properly adjust for potential confounding factors.
However, our study has also limitations. The study was of observational, cross-sectional design with a
relatively small cohort of IBD patients in which the primary outcome (endoscopic disease activity) was
only available from a subset (n = 54) of patients. Most importantly, no IBD patients with disease in
remission were included, which could have enabled us to assess the discriminative ability of serum free
thiols between quiescent and active disease and to establish clinically relevant cut-off values. In line,
we argued that our study was not appropriately designed to produce clinically useful cut-off values for
mild vs. moderate-to-severe disease activity as this would require a prospective diagnostic study with
serial assessments and larger sample sizes. Instead, we selected patients with at least some degree of
disease activity, aiming to examine serum free thiols as potential biomarker for disease activity. Finally,
time intervals between serum sampling and the endoscopy procedure varied among patients, leading
to a certain degree of temporal heterogeneity that could potentially have biased our results, or may
have resulted in an underestimation of the currently established correlation with disease activity.
5. Conclusions
In conclusion, we show that albumin-adjusted serum free thiols are significantly reduced in IBD
as compared to healthy individuals and are in line with the degree of endoscopically proven disease
activity. Furthermore, we show that serum free thiol levels significantly negatively correlate to fecal
calprotectin levels and may aid in differentiating mild from moderate-to-severely active IBD as assessed
by endoscopy. Future studies are warranted to further externally validate serum free thiol levels as
potential biomarker for IBD disease activity in larger, prospective patient cohorts and assess their value
in relation to disease course and therapeutic interventions.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/8/9/351/s1,
Figure S1: Albumin-adjusted serum free thiols (R-SH) are normally distributed among healthy controls (A) and
IBD patients (B). Figure S2: Albumin-adjusted serum free thiol concentrations (µmol/g) do not significantly differ
among different disease localizations in both Crohn’s disease (ileal [L1], colonic [L2] or ileocolonic [L3] disease)
and ulcerative colitis (left-sided colitis [E2] or pancolitis [E3]). Figure S3: Age, disease duration, platelets and fecal
calprotectin levels are independently associated with albumin-adjusted serum free thiols (correlations are shown
from univariable analysis). Figure S4: Albumin-adjusted serum free thiol (R-SH) levels accurately discriminate
between mild (1) and moderate-to-severe (2-3) endoscopic disease activity (AUC = 0.89, blue curve) after k-fold
cross-validation (k = 10) (dashed curves). Table S1: Univariable and multivariable linear regression analyses of
albumin-adjusted serum free thiols (R-SH) in Crohn’s disease (CD) with clinical and biochemical parameters.
Table S2: Univariable and multivariable linear regression analyses of albumin-adjusted serum free thiols (R-SH)
in ulcerative colitis (UC) with clinical and biochemical parameters. Table S3: ROC curve coordinates for both
serum free thiols (R-SH) and fecal calprotectin levels, showing all x-axis coordinates (step values of the false
positive rate, FPR) with corresponding sensitivity ranges (%). Table S4: Univariable logistic regression analysis
with demographic and clinical factors of IBD patients with regards to endoscopic (mild vs. moderate-to-severe)
disease activity prior to serum sample analysis. Table S5: Results from k-fold cross-validation (k = 10) of the final
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adjusted model containing serum free thiols, resulting in a cross-validated area under the curve (AUC) of 0.89
(95% CI: 0.63–0.93).
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